Anxiolytic and antidepressant effects of emoxipine, reamberin and mexidol in experimental diabetes mellitus

Abstract

All studied medications used in doses equivalent to therapeutic range in humans and administered for 14 days significantly reduced manifestations of anxiety and depression in rats with alloxan diabetes. The most pronounced anxiolytic potential was demonstrated for emoxipine that emerged as the only medication in the study that reduced manifestations of anxiety not only in comparison with 'alloxan diabetes-control' groups but also in comparison to 'intact control'. The intensity of tranquilizing activity of derivatives of 3-oxypyridine and succinic acid was similar to that of α-LA while the thymoanaleptic activity, when the drugs were administered in maximal doses to rats with experimental DM, was higher. Both emoxipine and mexidol as well as α-LA in all studied doses significantly decreased hyperglycemia in alloxan diabetes. Reamberin demonstrated only insignificant tendencies of the same trend.

The effect of methylethylpiridinol addition to the therapy on the level of pigment epithelium-derived factor and oxidative status in patients with diabetic nephropathy: randomized controlled open-label clinical study

“…An alternative approach to pharmacotherapy of DN complications could conclude in using 3-oxypyridine derivatives, particularly methylethylpiridinol hydrochloride. Experimental studies showed its potentiating activity towards insulin, capacity for increasing tolerance to glucose loading, antihypoxic and neuroprotective action in acute cerebrovascular pathologies [11].…”